Health And Pharma

FDA Approves Durvalumab as First Perioperative Immunotherapy for Gastric and GEJ Cancers

Durvalumab (Imfinzi) combined with FLOT chemotherapy has been approved by the FDA as the first perioperative immunotherapy ...
Health And Pharma

FDA Approves Keytruda–Padcev Combination as First Perioperative Treatment for Bladder Cancer

The FDA has approved pembrolizumab (Keytruda) or pembrolizumab Qlex with enfortumab vedotin (Padcev) as the first ...
Health And Pharma

Sevabertinib Wins FDA Approval with Strong Responses in HER2-Mutated NSC Lung Cancer

The FDA has granted accelerated approval to sevabertinib (Hyrnuo), for previously treated HER+ metastatic non-squamous ...
Health And Pharma

FDA Approves Ziftomenib as First Targeted Therapy for (R or R) NPM1+ Acute Myeloid Leukemia

The FDA has approved ziftomenib (KOMZIFTI), the first oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). In the KOMET-001 trial, the therapy ...
Health And Pharma

Ribociclib Extends Disease-Free Survival Beyond Treatment in HR+/HER2– Early Breast Cancer

Five-year data from the Phase III NATALEE trial confirm that adjuvant ribociclib (Kisqali) plus endocrine therapy reduces recurrence risk by 28% in patients with HR+/HER2– early breast cancer. The ...
healthandpharma

Disarming Prostate Cancer: Dual Enzyme Blockade Weakens Tumors and Boosts Drug Response

A new PNAS study unveils a hidden vulnerability of prostate cancer: the protein-disulfide isomerases PDIA1 and PDIA5, which stabilize androgen receptor and sustain tumor survival. Inhibition of these ...
healthandpharma

Molecular Trojan Horse: Peptide Nanotubes Offer a Path to Defeat Drug-Resistant Tumors

Researchers at CiQUS have developed self-assembling peptide nanotubes that deliver doxorubicin directly into the nucleus of drug-resistant cancer cells, restoring the chemotherapy’s potency. The ...
healthandpharma

Reprogramming Cancer Cell Death: A New Immune-Based Strategy for Blood Cancers

A new study published in Science Advances reveals a groundbreaking approach that makes cancer cells turn against themselves by reprogramming how they die. Scientists at the Institut Pasteur and Inserm ...
healthandpharma

AstraZeneca makes deal with Trump Admin to Cut Drug Prices 80% and Invest $50B in US

AstraZeneca has reached a wide-ranging agreement with the Trump administration to cut prescription drug prices for American patients—offering up to 80% discounts via TrumpRx.gov—while investing $50 ...
healthandpharma

LED-Activated SnOx Nanoflake Therapy Destroy Tumor Cells with Precision

Researchers from The University of Texas at Austin and the University of Porto have developed a groundbreaking LED-based cancer therapy using tin oxide (SnOx) nanoflakes that selectively destroy tumor ...
healthandpharma

In Vivo CAR T on the Horizon: BMS Acquires Orbital to Expand Cell Therapy Reach

Bristol Myers Squibb (BMS) has announced the acquisition of Orbital Therapeutics, a privately held biotech specializing in RNA-based immune reprogramming, in a $1.5 billion cash deal. The move ...
healthandpharma

FDA Approves Libtayo as First Adjuvant Immunotherapy for High-Risk CS Cell Carcinoma

The U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo® (cemiplimab-rwlc) as the first and only immunotherapy for the adjuvant treatment of cutaneous squamous cell ...